Antidepressants in Pregnancy May Contribute to Autism in Child

Share this content:
Antidepressants in Pregnancy May Contribute to Autism in Child
Antidepressants in Pregnancy May Contribute to Autism in Child

THURSDAY, July 20, 2017 (HealthDay News) -- In the long-standing debate over whether antidepressants are safe to take during pregnancy, a new study, published online July 19 in The BMJ, suggests that exposure to the drugs in the womb might increase a child's risk of autism.

Dheeraj Rai, Ph.D., a senior lecturer in psychiatry with the University of Bristol in the United Kingdom, and colleagues analyzed data from 254,610 children aged 4 to 17 living in Stockholm between 2001 and 2011. The researchers note that 5,378 of the children were diagnosed with autism, 3,342 of the children were exposed to antidepressants during pregnancy, and 12,325 children were born to mothers with psychiatric disorders who weren't taking an antidepressant in pregnancy.

Of the children exposed to antidepressants, 4.1 percent had been diagnosed with autism; 2.9 percent of children born to a woman with a history of psychiatric problems who didn't take antidepressants during pregnancy developed autism (adjusted odds ratio, 1.45; 95 percent confidence interval, 1.13 to 1.85). Antidepressants were more strongly associated with cases of autism that didn't include intellectual disability.

"The association between antidepressant use during pregnancy and autism, particularly autism without intellectual disability, might not solely be a byproduct of confounding. Study of the potential underlying biological mechanisms could help the understanding of modifiable mechanisms in the etiology of autism," the authors write. "Importantly, the absolute risk of autism was small, and, hypothetically, if no pregnant women took antidepressants, the number of cases that could potentially be prevented would be small."

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths